Skip to main content
Top
Published in: Rheumatology International 5/2015

01-05-2015 | Letter to the Editor - Cases with a Message

A case of PRES in an active lupus nephritis patient after treatment of corticosteroid and cyclophosphamide

Authors: M. Jabrane, Z. Ait Lahcen, W. Fadili, I. Laouad

Published in: Rheumatology International | Issue 5/2015

Login to get access

Abstract

Posterior reversible encephalopathy syndrome (PRES) is primarily a radiological diagnosis. The syndrome is characterized by headache, altered mental status, seizures, and bilateral posterior white matter edema in a nonvascular distribution on neuroimaging with resolution of findings usually in 7–14 days (Casey et al. in AJNR Am J Neuroradiol 21:1199–1206, 2000). In most cases, computed tomography of the brain will show hypodense lesions in the parieto-occipital lobe. Although this syndrome is uncommon, prompt and accurate recognition allows early treatment, which has been shown to produce favorable outcomes. It is hypothesized that the dysfunction can be caused by a failure of autoregulation systemic hypertension or by the cytotoxic effects of vasculitides and immunosuppressive drugs. The present report is a possible second case of cyclophosphamide-induced PRES in a 16-year-old girl with systemic lupus erythematous and lupus nephritis. The initial suspected diagnosis was an ischemic stroke, but it was later changed, with resolution of symptoms after management of the underlying cause.
Literature
1.
go back to reference Casey SO, Sampaio RC, Michel E, Truwit CL (2000) Posterior reversible encephalopathy syndrome: utility of fluidattenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions. AJNR Am J Neuroradiol 21:1199–1206PubMed Casey SO, Sampaio RC, Michel E, Truwit CL (2000) Posterior reversible encephalopathy syndrome: utility of fluidattenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions. AJNR Am J Neuroradiol 21:1199–1206PubMed
2.
go back to reference Hinchey J, Chaves C, Appignani B et al (1996) A reversible posterior leucoencephalopathy syndrome. N Engl J Med 334:494–500CrossRefPubMed Hinchey J, Chaves C, Appignani B et al (1996) A reversible posterior leucoencephalopathy syndrome. N Engl J Med 334:494–500CrossRefPubMed
3.
go back to reference Casey SO, Sampaio RC, Michel E, Truwit CL (2000) Posterior reversible encephalopathy syndrome: utility of fl uid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions. AJNR Am J Neuroradiol 21(7):1199–1206PubMed Casey SO, Sampaio RC, Michel E, Truwit CL (2000) Posterior reversible encephalopathy syndrome: utility of fl uid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions. AJNR Am J Neuroradiol 21(7):1199–1206PubMed
4.
go back to reference Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA (2010) Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc 85(5):427–432CrossRefPubMedCentralPubMed Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA (2010) Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc 85(5):427–432CrossRefPubMedCentralPubMed
5.
go back to reference Ni J, Zhou LX, Hao HL et al (2011) The clinical and radiological spectrum of posterior reversible encephalopathy syndrome: a retrospective series of 24 patients. J Neuroimaging 21:219–224CrossRefPubMed Ni J, Zhou LX, Hao HL et al (2011) The clinical and radiological spectrum of posterior reversible encephalopathy syndrome: a retrospective series of 24 patients. J Neuroimaging 21:219–224CrossRefPubMed
6.
go back to reference Varaprasad IR, Agrawal S, Prabu VN, Rajasekhar L, Kanikannan MA, Narsimulu G (2011) Posterior reversible encephalopathy syndrome in systemic lupus erythematosus. J Rheumatol 38:1607–1611CrossRefPubMed Varaprasad IR, Agrawal S, Prabu VN, Rajasekhar L, Kanikannan MA, Narsimulu G (2011) Posterior reversible encephalopathy syndrome in systemic lupus erythematosus. J Rheumatol 38:1607–1611CrossRefPubMed
7.
go back to reference Kur JK, Esdaile JM (2006) Posterior reversible encephalopathy syndrome—an underrecognized manifestation of systemic lupus erythematosus. J Rheumatol 33(11):2178–2183PubMed Kur JK, Esdaile JM (2006) Posterior reversible encephalopathy syndrome—an underrecognized manifestation of systemic lupus erythematosus. J Rheumatol 33(11):2178–2183PubMed
8.
go back to reference Ishimori ML, Pressman BD, Wallace DJ, Weisman MH (2007) Posterior reversible encephalopathy syndrome: another manifestation of CNS SLE? Lupus 16(6):436–443CrossRefPubMed Ishimori ML, Pressman BD, Wallace DJ, Weisman MH (2007) Posterior reversible encephalopathy syndrome: another manifestation of CNS SLE? Lupus 16(6):436–443CrossRefPubMed
9.
go back to reference Gasparovic C, Qualls C, Greene ER, Sibbitt WL, Roldan CA (2012) Blood pressure and vascular dysfunction underlie elevated cerebral blood flow in systemic lupus erythematosus. Rheumatology 39(4):752–758CrossRef Gasparovic C, Qualls C, Greene ER, Sibbitt WL, Roldan CA (2012) Blood pressure and vascular dysfunction underlie elevated cerebral blood flow in systemic lupus erythematosus. Rheumatology 39(4):752–758CrossRef
10.
go back to reference Matsui A, Ikeuchi H, Shimizu A et al (2012) Posterior reversible encephalopathy syndrome and scleroderma renal crisis developed in a patient with overlap syndrome after treatment with high-dose steroids and tacrolimus. Nihon Naika Gakkai Zasshi 101(7):2051–2054CrossRefPubMed Matsui A, Ikeuchi H, Shimizu A et al (2012) Posterior reversible encephalopathy syndrome and scleroderma renal crisis developed in a patient with overlap syndrome after treatment with high-dose steroids and tacrolimus. Nihon Naika Gakkai Zasshi 101(7):2051–2054CrossRefPubMed
11.
go back to reference Ishikura K, Ikeda M, Hamasaki Y et al (2006) Posterior reversible encephalopathy syndrome in children: its high prevalence and more extensive imaging findings. Am J Kidney Dis 48:231–238CrossRefPubMed Ishikura K, Ikeda M, Hamasaki Y et al (2006) Posterior reversible encephalopathy syndrome in children: its high prevalence and more extensive imaging findings. Am J Kidney Dis 48:231–238CrossRefPubMed
12.
go back to reference Cellucci T, Benseler SM (2011) Posterior reversible encephalopathy syndrome: increasing recognition of an important clinical entity in young patients with systemic lupus erythematosus. J Rheumatol 38:1544–1545CrossRefPubMed Cellucci T, Benseler SM (2011) Posterior reversible encephalopathy syndrome: increasing recognition of an important clinical entity in young patients with systemic lupus erythematosus. J Rheumatol 38:1544–1545CrossRefPubMed
14.
go back to reference Zhang Y, Liu J, Ding M et al (2008) Reversible posterior encephalopathy syndrome in systemic lupus erythematosus and lupus nephritis. Intern Med 47:867–875CrossRefPubMed Zhang Y, Liu J, Ding M et al (2008) Reversible posterior encephalopathy syndrome in systemic lupus erythematosus and lupus nephritis. Intern Med 47:867–875CrossRefPubMed
15.
go back to reference Kadikoy Huseyin et al (2012) Posterior reversible encephalopathy syndrome in a patient with lupus nephritis. Saudi J Kidney Dis Transpl 23(3):572–576PubMed Kadikoy Huseyin et al (2012) Posterior reversible encephalopathy syndrome in a patient with lupus nephritis. Saudi J Kidney Dis Transpl 23(3):572–576PubMed
Metadata
Title
A case of PRES in an active lupus nephritis patient after treatment of corticosteroid and cyclophosphamide
Authors
M. Jabrane
Z. Ait Lahcen
W. Fadili
I. Laouad
Publication date
01-05-2015
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 5/2015
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-014-3173-1

Other articles of this Issue 5/2015

Rheumatology International 5/2015 Go to the issue

Letter to the Editor - Critique and Appraisal

The lack of efficacy of oxytocin and NSAIDs

Original Article - Cases with a Message

Osseous sarcoidosis: a case series

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.